takeda pharmaceutical co reported fourthquarter results on wednesday heres what we watched net loss takeda pharmaceutical posted a net loss of 114 billion yen 874 million for the quarter ended march that missed the estimate of y1596 billion taken from a poll of analysts by sp global market intelligence revenue revenue increased 13 from a year earlier to y8733 billion that was better than the estimate of y84814 billion in the poll by sp global market intelligence drug sales takedas revenue growth was led by several key drugs sales of ulcerative colitis drug entyvio increased 15 from a year earlier to y1264 billion while sales of vyvanse a drug for attention deficit hyperactivity disorder rose 19 to y821 billion operating loss cost of sales and researchanddevelopment expenses increased more sharply than revenue leading to an operating loss russia takeda said revenue for russia and commonwealth of independent states was y621 billion for the fiscal year ended march or 17 of total revenue and that there was no material financial impact on its financial results stemming from the crisis in the region